Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BLU

BELLUS Health (BLU) Stock Price, News & Analysis

BELLUS Health logo

About BELLUS Health Stock (NASDAQ:BLU)

Key Stats

Today's Range
$14.74
$14.75
50-Day Range
$14.42
$14.75
52-Week Range
$6.38
$14.76
Volume
3.45 million shs
Average Volume
3.08 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

BLU Stock Analysis - Frequently Asked Questions

BELLUS Health Inc. (NASDAQ:BLU) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative net margin of 578,586.63% and a negative trailing twelve-month return on equity of 24.27%.

Based on aggregate information from My MarketBeat watchlists, some other companies that BELLUS Health investors own include NIO (NIO), Meta Platforms (META), Pfizer (PFE), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Tesla (TSLA) and Ford Motor (F).

Company Calendar

Last Earnings
11/10/2021
Today
11/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLU
Employees
74
Year Founded
N/A

Profitability

Net Income
$-76,080,000.00
Net Margins
-578,586.63%
Pretax Margin
-578,226.56%

Debt

Sales & Book Value

Annual Sales
$15,000.00
Price / Sales
124,613.93
Book Value
$3.09 per share

Miscellaneous

Free Float
96,162,000
Market Cap
$1.87 billion
Optionable
Not Optionable
Beta
0.19
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:BLU) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners